Loading data for LENZ — first visit, this takes a few seconds.

알림

LENZ Therapeutics Inc. (LENZ)

NasdaqGS: LENZ · 실시간 가격 · USD

4.75

+0.08 (1.71%)

종가 기준: Aug 27, 2026, 5:03 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

1.71% (1D)

데이터 없음

매수호가	4.67
시가총액	150.5M
매출 (ttm)	21.48M
순이익 (ttm)	-126M
	1.63
	-4.13
	n/a
	-1.56
P/B (ttm)	0.69
P/S (ttm)	7.01
실적 발표일	Nov 4, 2026

매도호가	5.91
거래량	223,155
평균 거래량 (20일)	861,990
시가	4.67
전일 종가	4.67
일중 범위	4.60 - 4.83
52주 범위	4.54 - 50.40
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

LENZ 소개

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headqua...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jun 25, 2021

직원 수 152

상장 거래소 NasdaqGS

티커 LENZ

웹사이트 https://www.lenz-tx.com

전체 기업 정보

재무 실적

2025년 LENZ Therapeutics의 매출은 19.09M로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -82.13M로, 65.02% 증가했습니다.

재무제표

어닝 서프라이즈

LENZ Therapeutics가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $1.9M 예상치 하회 $0, 및 Infinity% 전년 대비 성장.
EPS -1.02 예상치 상회 0.05, 및 -92.45% 전년 대비 감소.

다음 실적 발표

LENZ Therapeutics Inc.의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Motley Fool

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript

Prescription growth surged 45% in July after telehealth launch.

1주 전 · Simply Wall St.

LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts

The analyst fair value estimate for LENZ Therapeutics has shifted from US$32.00 to about US$26.83 per share, which now lines up more closely with the US$7 price target cluster that many firms referenc...

2주 전 · GuruFocus.com

LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ...

Strong cash position and expanding global partnerships offset modest Q2 product revenue growth as the company scales commercial execution.

2주 전 · Moby

LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary

Moby summary of LENZ Therapeutics, Inc.'s Q2 2026 earnings call

2주 전 · MarketBeat

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics (NASDAQ:LENZ) reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity foll...

2 페이지 중 1

LENZ Therapeutics Inc. (LENZ)